The lack of a gold standard tool that is high in sensitivity and specificity for diagnosing the etiology of pneumonia is a major hurdle in defining the efficacy and potential public health benefit of vaccines against pneumonia in children. Although the World Health Organization (WHO) clinical criteria for the diagnosis of severe pneumonia are highly sensitive (∼80%), they have a low positive predictive value (25%) [1, 2] . In contrast, blood cultures in individuals with pneumonia lack sensitivity (10%-15%) but have good specificity for defining the bacterial etiology of pneumonia [3] .
Although lung puncture taps are an alternate strategy for determining an etiological diagnosis of pneumonia, they are rarely used and are mainly performed in cases in which there is a distinctly accessible area of consolidation [4] . On the basis of the postulate that the most likely chest radiographic manifestation of pneumococcal pneumonia is alveolar consolidation [5] , a working group of the WHO recently published guidelines for the interpretation and reporting of chest radiographs [5] . Chest radiographs, however, have been found to be unreliable for distinguishing between bacterial and viral pneumonia [6] [7] [8] . This study determined the efficacy of pneumococcal conjugate vaccine (PnCV) and measured the relative burden of disease prevented through vaccination by comparing different outcome measures that could be used as surrogate markers of pneumococcal pneumonia.
METHODS
We have previously reported on the efficacy of a 9-valent PnCV in reducing the rate of chest radiograph-confirmed pneumonia [9] and against clinically and/or radiographicly confirmed pneumonia [10] . The purpose of the current hypothesis-generating analysis was to compare the relative sensitivity of the above-mentioned outcomes with those of blood culture-confirmed pneumococcal pneumonia and various modifications of WHO-defined clinically diagnosed pneumonia [1] to determine which of the outcome measures provides the best estimate of the burden of pneumococcal pneumonia prevented by vaccination.
Study population. The demographic information for the children participating in this study has been detailed elsewhere [9] . In brief, the study was a double-blind, placebo-controlled trial that included 39,836 children who were randomized to receive either a 9-valent PnCV (Wyeth Vaccines and Pediatrics) or placebo at 6, 10, and 14 weeks of age.
Passive surveillance for all-cause hospitalization was conducted by study staff at the local hospital (Chris Hani-Baragwanath Hospital; Soweto, South Africa). Indications for hospitalization were at the discretion of the hospital physicians. All children were examined by one of the study staff when hospitalized for any illness. A standard examination form was completed that captured clinical signs and symptoms of lower respiratory tract infection (LRTI). Outcome cases included in this report were those that occurred through 15 November 2001.
HIV-1 prevalence and testing. On the basis of the measured prevalence of HIV infection among women attending antenatal clinics during the course of the study period (22.5%-27.8%), it was estimated that 24.87% of the children enrolled into the study were born to HIV-infected mothers [11] . Furthermore, on the basis of the estimated vertical transmission rate of HIV infection from mother to child in the absence of any antiretroviral intervention (26%) [12] , it was estimated that 6.47% of the children recruited into either arm of the study were infected with HIV. The denominators for calculating the incidence rate and vaccine-attributable reduction (VAR) in disease in HIV-infected and HIV-uninfected children were based on the estimates above. Testing for HIV infection status of children hospitalized with LRTIs was performed as described elsewhere [9] .
Bacterial cultures. Blood samples were cultured for bacterial growth at admission to the hospital for all children with suspected LRTI and were processed using the BacT/Alert microbial detection system (Organon Teknika), and isolates of Streptococcus pneumoniae were serotyped as described elsewhere [9] .
Chest radiographs. Chest radiographs were obtained for all children with a suspected LRTI and were interpreted for the presence of alveolar infiltrate using WHO recommendations for reporting [5, 9] .
Definitions. The efficacy of the vaccine against possible pneumococcal pneumonia was analyzed using the following outcome measures. WHO-confirmed radiological pneumonia (WHO-AC) was defined as pneumonia associated with chest radiograph-confirmed alveolar consolidation (i.e., the presence of a dense opacity that could be a fluffy consolidation of a portion of a lobe, a whole lobe, or the entire lung, often containing air bronchograms and sometimes associated with pleural effusion, or a pleural effusion in the lateral pleural space associated with a pulmonary infiltrate or an effusion large enough to obscure such an opacity), in accordance with WHO recommendations [5] . Clinical LRTI (C-LRTI) was defined to include cases in all children hospitalized with a study physician diagnosis of pneumonia or bronchiolitis, irrespective of their clinical or radiographic features. Clinical pneumonia was defined as the presence of WHO-AC or was considered to have occurred if the child fulfilled the clinical diagnosis of LRTI without wheeze on chest auscultation but had crackles and/or bronchial breathing on chest wall auscultation [10] . Bronchiolitis was defined as the presence of wheezing on chest auscultation performed by one of the study doctors in the absence of documented alveolar consolidation (i.e., WHO-AC) on chest radiography or bronchial breathing on chest wall auscultation. WHO-defined mild pneumonia was defined as cough of !14 days duration in a child with tachypnea (defined as 150 breaths/ min in children !12 months of age and 140 breaths/min in children у12 months of age) in the absence of lower chest wall in-drawing or other signs and symptoms of WHO-defined severe pneumonia [1] . WHO-defined severe pneumonia was defined as a cough of !14 days duration in a child with lower chest wall in-drawing and/or any of the following signs and symptoms of severe pneumonia: feeding difficulties, convulsions, central cyanosis, or encephalopathy [1] . Bacteremic pneumococcal pneumonia was defined as pneumonia associated with a blood culture positive for S. pneumoniae, irrespective of the serotype. Vaccine serotype-specific bacteremic pneumococcal pneumonia was defined as pneumonia associated with a blood culture positive for S. pneumoniae belonging to 1 of the 9 vaccine serotypes. VAR was defined as the burden of disease prevented expressed in number of cases per 100,000 child-years of observation.
Statistical methods. Data were analyzed using Stata software, version 8.0 (StataCorp), and EpiInfo software, version 6.04d (Centers for Disease Control and Prevention). Vaccine efficacy (VE) was calculated using the VE calculation function in EpiInfo software for cohort studies. This is based on the formula VE (expressed as a percentage) p {(attack rate in the unvaccinatedϪattack rate in the vaccinated)/attack rate in the unvaccinated} ϫ 100. VAR was calculated on the basis of the formula VAR p (incidence rate of disease in the unvaccinated cohortϪincidence rate of disease in the vaccinated cohort)/ median follow-up time (which was 847.5 days in the PnCV group and 847 days in the placebo group) and expressed as number of cases per 100,000 child-years of observation. Categorical data were analyzed using the Pearson x 2 test or the Yates x 2 test if an expected cell value was !5. A P value of р.05 was considered statistically significant.
All analyses performed on an intent-to-treat (ITT) basis included any child that had received at least a single dose of study vaccine from the date of receiving the first dose of study vaccine; per-protocol analysis included only children who had received 3 doses of the same study vaccine within protocol-defined time periods [9] . Only the first episode of an event per individual was considered for all analyses.
Ethical issues. This study was approved by the Ethics Committee for research on Human Subjects of the University of the Witwatersrand (Johannesburg, South Africa), and signed informed consent was obtained from the parent or legal guardian of the children at the time of enrollment into the study.
RESULTS

VE in entire study cohort irrespective of the HIV status of the children.
Among children with C-LRTI who were included in the ITT analysis, chest radiographs were unavailable for 115 (7.7%) of 1493 vaccinees and 119 (7.2%) of 1646 placebo recipients ( ); blood cultures were not performed for 55 P p .61 (3.7%) of the vaccinees and 72 (4.4%) of the placebo recipients with C-LRTI ( ). P p .33 Although the point estimate of VE was greatest for vaccine serotype-specific bacteremic pneumococcal pneumonia (60.9%), the outcome measure of clinical pneumonia was the most sensitive in measuring the burden of pneumococcal pneumonia prevented by vaccination (VAR, 410 cases per 100,000 child-years; table 1). Using the outcome of clinical pneumonia as the benchmark of the burden of disease prevented by vaccination, the sensitivity of other outcome measures to detect the burden of pneumococcal pneumonia prevented was determined by comparing the measured VAR with the VAR of clinical pneumonia (VAR, 410 cases per 100,000 child-years). The sensitivities of WHO-defined severe pneumonia (VAR, 279 cases per 100,000 child-years), WHO-AC (VAR, 155 cases per 100,000 child-years), and pneumococcal bacteremic pneumonia (VAR, 37 cases per 100,000 child-years) in detecting the burden of disease prevented through vaccination were 68.0% (95% CI, 63.3%-72.5%), 37.8% (95% CI, 33.1%-42.7%), and 9.0% (95% CI, 6.4%-1.2%), respectively. However, vaccinees were more likely than other subjects to be hospitalized for WHO-defined mild pneumonia (relative risk [RR], 1.2; 95% CI, 1-1.46), although this increase was not statistically significant when children with concurrent wheezing were excluded ( ) (table 1) . The sensi-P p .001 tivities of WHO-defined severe pneumonia (VAR, 164 cases per 100,000 child-years), WHO-AC (VAR, 100 cases per 100,000 child-years), and pneumococcal bacteremic pneumonia (VAR, 7 cases per 100,000 child-years), relative to the clinical pneumonia outcome in measuring the burden of pneumonia prevented by the PnCV, were 61.4% (95% CI, 55.3%-66.3%), 37.5% (95% CI, 31.6%-43.6%), and 2.6% (95% CI, 1.0%-5.3%), respectively.
The lower sensitivity (64.4%; 95% CI, 58.4%-70.2%) of C-LRTI (VAR, 172 cases per 100,000 child-years) for detection of the burden of pneumonia prevented through vaccination was most likely because of an excess (RR, 1.3; 95% CI, 1.1-1.6) of WHO-defined mild pneumonia observed among vaccinees (table 2). As observed for the entire cohort of children, the burden of WHO-defined mild pneumonia was greater for vaccinees than for placebo recipients in the ITT ( ) and per-pro-P p .02 tocol analyses ( ); however, this was not statistically sig-P p .02 nificant when children with wheezing were excluded (table 2). There was a nonsignificant decrease in the overall (ITT) incidence of mechanical ventilation and a trend of fewer deaths from C-LRTI in vaccinees (table 2) .
VE against pneumonia in HIV-infected children. Chest radiographs were unavailable for 35 (8.5%) of 412 vaccinees and 47 (9.7%) of 487 placebo recipients for their first episodes of C-LRTI ( ); blood culture results were unavailable for P p .59 8 (1.9%) of the vaccinees and 13 (2.7%) of the placebo recipients ( ). P p .47 Despite the lack of a statistically significant difference between vaccinees and placebo recipients for WHO-AC (13%;
), vaccinees had a significantly lower incidence of hos-P p .19 pitalization when evaluating the outcomes of C-LRTI (15%;
), clinical pneumonia (15%; ), and WHO-P p .002 P p .004 defined severe pneumonia (17%;  (table 3) . The out-P p .006 come measure with the greatest sensitivity for detecting the burden of pneumococcal pneumonia prevented by vaccination in HIV-infected children was that of C-LRTI (VAR, 2573 cases per 100,000 child-years), and this was used as the benchmark in evaluating the sensitivity of the other outcomes for determining the burden of pneumonia prevented by vaccination. Although the VE estimate was greatest for vaccine serotypespecific bacteremic pneumococcal pneumonia (VE, 59%; ), the sensitivity of this outcome (VAR, 344 cases per P p .04 100,000 child-years) in measuring the burden of pneumonia prevented through vaccination was 13.4% (95% CI, 12.1%-14.7%). Relative to the outcome for C-LRTI, the sensitivities of clinical pneumonia (VAR, 2302 cases per 100,000 childyears), WHO-defined severe pneumonia (VAR, 2052 cases per 100,000 child-years), WHO-AC (VAR, 909 cases per 100,000 child-years), and all bacteremic pneumococcal pneumonia (VAR, 483 cases per 100,000 child-years) in detecting the burden of pneumococcal pneumonia prevented by vaccination were 89.5% (95% CI, 88.2%-90.6%), 79.8% (95% CI, 78.1%-81.3%), 35.3% (95% CI, 33.5%-37.2%), and 18.8% (95% CI, 17.3%-20.3%), respectively (table 3 ). An estimated 10.9% of the HIV-infected children (281 of 2577) died from C-LRTI, with no difference in rates observed between vaccinees and placebo recipients.
DISCUSSION
This report provides insight into the clinical presentation of pneumococcal pneumonia in HIV-infected and -uninfected children. We show that an outcome measure with high specificity, such as bacteremic pneumococcal pneumonia, yields the highest point efficacy estimate for the PnCV but has a very limited role when evaluating the potential public health benefit of the PnCV.
The outcome measures that most accurately evaluated the impact of the PnCV on the public health burden of pneumonia were C-LRTI (in HIV-infected children) and clinical pneumonia (in HIV-uninfected children). Although the primary objective of the study was to measure the efficacy of the vaccine against chest radiograph-confirmed alveolar consolidation [9] , the current hypothesis-generating study suggests that only 37.8% of patients with pneumococcal pneumonia presented with chest radiograph-confirmed alveolar consolidation. Although a radiological lag in the chest radiograph changes in relation to the clinical presentation may explain, in part, the low frequency of chest radiograph-confirmed alveolar consolidation, it would appear that most cases of pneumococcal pneumonia do not manifest themselves as alveolar consolidation on chest radiographs. This observation, in addition to the high frequency of concurrent pneumococcal infection in children with viral pneumonia (31%) [10] , may also explain why chest radiograph findings are unhelpful in discriminating between bacterial and viral causes of pneumonia [6] [7] [8] .
Clinical pneumonia end points themselves are subject to variation between individuals and within individuals. This misclassification bias has likely decreased the observed differences between vaccinees and placebo recipients and, therefore, the vaccine impact is likely to be an underestimation. Although all of the study physicians had previous pediatric experience, clinical review by an expert panel may be useful to standardize a clinical end point for a vaccine trial.
A paradoxical finding of our study was the excess in cases of WHO-defined mild pneumonia observed in vaccinees, particularly in HIV-uninfected children. The reason for hospitalization of these children, whom the WHO recommends be treated on an outpatient basis, was because the hospital provided a 24-h clinical service, and children with mild pneumonia sometimes slept at the hospital for logistical reasons. The incidence of WHO-defined mild pneumonia in this study is, however, an underestimation of the true burden of disease, because the majority of children with mild pneumonia would have been treated outside of the hospital, where surveillance for study outcomes was not undertaken.
The increase in WHO-defined mild pneumonia was evident only when all children were included in analysis, irrespective of the presence of wheezing on clinical examination. The excess of pneumonia was abolished when children with wheeze were excluded from the category of mild pneumonia. There are a number of possible, speculative reasons for why vaccinees were at increased risk of developing WHO-defined mild pneumonia with wheeze. Immunity induced through vaccination may have attenuated the clinical course of illness, with vaccinees less likely than placebo recipients to progress to severe disease. Although vaccination was successful in reducing concurrent pneumococcal superinfection in patients with viral-associated pneumonia [10] , the clinical course of the viral-associated LRTI may have been altered in vaccinees. This may result in vaccinees with viral infections experiencing progression to WHO-defined mild pneumonia with wheezing rather than to WHO-defined severe pneumonia, which would have resulted had the vaccine not protected against superimposed pneumococcal infection.
Importantly, the excess of cases of WHO-defined mild pneumonia was not significant when children with wheezing were excluded from the analyses, and furthermore, the vaccine had no measurable effect on bronchiolitis. These data support the low likelihood of a role for the pneumococcus in children who present with these clinical signs and symptoms (i.e., mild pneumonia with wheeze and bronchiolitis), although our study lacked the power to detect a very small impact of vaccination on these conditions. Our data suggest that the criteria for administration of antibiotics may be refined to exclude children who have wheezing as their only clinical sign, although a role for other bacteria in this presentation cannot be excluded by our study. The use of auscultation would, however, require the additional training of nonphysician health workers in the evaluation of chest auscultation as part of clinical assessment.
Although we only observed trends toward fewer episodes requiring mechanical ventilation support and fewer deaths in HIV-uninfected children, these results need to be interpreted in the context of the lack of power of our study to evaluate such outcomes. Furthermore, unlike in most other developing countries and many rural areas of South Africa, health care services, including oxygen and appropriate antibiotic therapy, were freely available and accessible to all children in the study area. This is evident in the low overall case-fatality rate associated with LRTI in HIV-uninfected children (40 [1.9%] of 2139 episodes).
The vaccine was not efficacious in reducing mortality in HIVinfected children, in whom the overall case-fatality rate due to LRTI (281 [31.3%] of 899 children) was 16.7-fold greater (95% CI, 14.5-19.3-fold greater) than that observed in HIV uninfected children (1.9%). This may be due to the complexity of pneumonia in these children [13] . HIV-infected children may have been disadvantaged because of the hospital's policy of not providing mechanical ventilation to HIV-infected children. However, this is unlikely to have been the dominant reason for the high mortality rate among these children, because a fatality rate of 190% was previously documented for HIV-infected children receiving mechanical ventilation for pneumonia in the absence of treatment with antiretroviral drugs at the same hospital [14] .
Although the determination of HIV status was made directly for patients with the outcomes reported in this study, the denominator of HIV-infected children at risk was based on indirect estimation. Direct determination of the HIV status of all children at study entry would have increased the precision of our vaccine impact analyses but would not have affected our estimates of the relative sensitivity of the clinical end points measured. Furthermore, the estimated burden of disease is so high that variance from these estimates is unlikely to greatly alter our assessment of vaccine impact.
Thus, although the PnCV did not reduce mortality among HIV-infected children, its relevance in improving the quality of life for these children was made evident by the greater burden (OR, 9.9; 95% CI, 8.7-11.2) of hospitalization for pneumococcal pneumonia prevented in HIV-infected children (VAR, 2573 cases per 100,000 child-years), compared with the burden prevented in HIV-uninfected vaccine recipients (VAR, 267 cases per 100,000 child-years). This is particularly important given that, among placebo recipients, the overall incidence of C-LRTI hospitalization for HIV-infected children was 6.4-fold greater (95% CI, 5.8-7.0-fold greater) than for HIV-uninfected children.
